Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2021 · fourth_quarter · 4T
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Source: Senate LDA
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Improving Patient Access to Care and Treatment Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Fairness in Orphan Drug Exclusivity Act
Client: BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2021 · fourth_quarter · Q4
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2021 · third_quarter · Q3
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2021 · second_quarter · Q2
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2021 · first_quarter · Q1
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2020 · fourth_quarter · Q4
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2020 · third_quarter · Q3
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2020 · second_quarter · Q2
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2020 · first_quarter · Q1
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2019 · fourth_quarter · Q4
General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act HR 4712-Fairness in Orphan Drug Exclusivity Act
General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act HR 4712-Fairness in Orphan Drug Exclusivity Act
General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act HR 4712-Fairness in Orphan Drug Exclusivity Act
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2019 · third_quarter · Q3
S. 1895: Lower Health Care Costs Act in reference to the Opioid Crisis General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act
S. 1895: Lower Health Care Costs Act in reference to the Opioid Crisis General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act
S. 1895: Lower Health Care Costs Act in reference to the Opioid Crisis General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2019 · second_quarter · Q2
S 1895: Lower Health Care Costs Act in reference to the Opioid Crisis
S 1895: Lower Health Care Costs Act in reference to the Opioid Crisis
S 1895: Lower Health Care Costs Act in reference to the Opioid Crisis
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2019 · first_quarter · Q1
Opioid Crisis, FDA approval process
Opioid Crisis, FDA approval process
Opioid Crisis, FDA approval process
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2018 · fourth_quarter · Q4
Opioid Crisis
Opioid Crisis
Opioid Crisis
Opioid Crisis
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2018 · third_quarter · Q3
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2018 · second_quarter · Q2
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2018 · first_quarter · Q1
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2017 · third_quarter · RA
Opioid Addiction Crisis
Opioid Addiction Crisis
Opioid Addiction Crisis
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2017 · fourth_quarter · Q4
Opioid Addiction Crisis S.916- Protecting Patient Access to Emergency Medications Act of 2017
Opioid Addiction Crisis S.916- Protecting Patient Access to Emergency Medications Act of 2017
Opioid Addiction Crisis S.916- Protecting Patient Access to Emergency Medications Act of 2017
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2017 · third_quarter · Q3
Opioid Addiction Crisis S.916- Protecting Patient Access to Emergency Medications Act of 2017
Opioid Addiction Crisis S.916- Protecting Patient Access to Emergency Medications Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC via BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
2017 · third_quarter · RR
Opioid Addiction Crisis
Opioid Addiction Crisis
Opioid Addiction Crisis
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances
Filing targets: Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Filing targets: HOUSE OF REPRESENTATIVES, Office of Natl Drug Control Policy (NDCP), SENATE
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act HR 4712-Fairness in Orphan Drug Exclusivity Act
General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act HR 4712-Fairness in Orphan Drug Exclusivity Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. 1895: Lower Health Care Costs Act in reference to the Opioid Crisis General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act
S. 1895: Lower Health Care Costs Act in reference to the Opioid Crisis General lobbying pertaining to opioid crisis, including amendments to the Orphan Drug Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S 1895: Lower Health Care Costs Act in reference to the Opioid Crisis
S 1895: Lower Health Care Costs Act in reference to the Opioid Crisis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Opioid Crisis, FDA approval process
Opioid Crisis, FDA approval process
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Opioid Crisis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S.916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.
HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Opioid Addiction Crisis
Opioid Addiction Crisis
Opioid Addiction Crisis
Opioid Addiction Crisis
Opioid Addiction Crisis S.916- Protecting Patient Access to Emergency Medications Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Opioid Addiction Crisis
Opioid Addiction Crisis
Opioid Addiction Crisis
Opioid Addiction Crisis